ATE491723T1 - Neue verbindungen mit gemischter amylin aktivität - Google Patents

Neue verbindungen mit gemischter amylin aktivität

Info

Publication number
ATE491723T1
ATE491723T1 AT99906782T AT99906782T ATE491723T1 AT E491723 T1 ATE491723 T1 AT E491723T1 AT 99906782 T AT99906782 T AT 99906782T AT 99906782 T AT99906782 T AT 99906782T AT E491723 T1 ATE491723 T1 AT E491723T1
Authority
AT
Austria
Prior art keywords
treating
diabetes
amylin
compounds
type
Prior art date
Application number
AT99906782T
Other languages
English (en)
Inventor
Nigel Beeley
Kathryn Prickett
Kevin Beaumont
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE491723T1 publication Critical patent/ATE491723T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99906782T 1998-02-13 1999-02-05 Neue verbindungen mit gemischter amylin aktivität ATE491723T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7474698P 1998-02-13 1998-02-13
PCT/US1999/002603 WO1999040928A1 (en) 1998-02-13 1999-02-05 Novel mixed amylin activity compounds

Publications (1)

Publication Number Publication Date
ATE491723T1 true ATE491723T1 (de) 2011-01-15

Family

ID=22121450

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99906782T ATE491723T1 (de) 1998-02-13 1999-02-05 Neue verbindungen mit gemischter amylin aktivität

Country Status (8)

Country Link
EP (1) EP1053001B1 (de)
JP (1) JP4372345B2 (de)
AT (1) ATE491723T1 (de)
AU (1) AU766653B2 (de)
CA (1) CA2320962C (de)
DE (1) DE69943039D1 (de)
ES (1) ES2356595T3 (de)
WO (1) WO1999040928A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1325028A2 (de) * 2000-09-19 2003-07-09 University Of Toronto Inhibitoren von iapp fibrillenbildung und ihre verwendungen
DE60140693D1 (en) 2000-12-14 2010-01-14 Amylin Pharmaceuticals Inc Ankheiten
CA2471833A1 (en) * 2001-11-26 2003-06-05 Protemix Corporation Limited Methods of compositions for normalizing lipid levels in mammalian tissues
US20070275877A1 (en) * 2003-08-29 2007-11-29 Amylin Pharmaceuticals, Inc. Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
DE602005021858D1 (de) 2004-02-11 2010-07-29 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
RS59977B1 (sr) 2011-06-10 2020-03-31 Novo Nordisk As Polipeptidi
CN104395338B (zh) * 2012-04-19 2019-05-10 诺和诺德股份有限公司 人胰岛淀粉样多肽类似物
PL3474820T3 (pl) 2017-08-24 2024-05-13 Novo Nordisk A/S Kompozycje glp-1 i ich zastosowania
EP4106724A1 (de) 2020-02-18 2022-12-28 Novo Nordisk A/S Glp-1-zusammensetzungen und verwendungen davon

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3640042A1 (de) 1985-12-04 1987-06-11 Sandoz Ag Neue calcitoninderivate
NL8602950A (nl) 1985-12-04 1987-07-01 Sandoz Ag Calcitonine-derivaten en werkwijzen voor het bereiden van deze derivaten en van farmaceutische preparaten die ze bevatten.
HU906340D0 (en) * 1986-10-13 1991-04-29 Sandoz Ag Synthesis in solid phase for producing peptonic alcohols
GB2218102B (en) 1988-04-08 1992-09-16 Sandoz Ltd Calcitonin peptide derivatives
US5321008A (en) 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
JP3628689B2 (ja) 1991-11-19 2005-03-16 ペプテック（ユーケイ）リミティド 敗血症性ショックの治療のためのムラミル化合物
WO1993014408A1 (en) 1992-01-14 1993-07-22 Amylin Pharmaceuticals, Inc. Myotonin receptors and screening methods
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
US5625032A (en) 1993-07-21 1997-04-29 Amylin Pharmaceuticals, Inc. Selective amylin antagonist peptides and uses therefor
WO1995007098A1 (en) * 1993-09-07 1995-03-16 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility

Also Published As

Publication number Publication date
CA2320962A1 (en) 1999-08-19
EP1053001B1 (de) 2010-12-15
JP2002522355A (ja) 2002-07-23
CA2320962C (en) 2011-04-19
WO1999040928A1 (en) 1999-08-19
DE69943039D1 (de) 2011-01-27
EP1053001A4 (de) 2006-01-04
EP1053001A1 (de) 2000-11-22
AU766653B2 (en) 2003-10-23
AU2661299A (en) 1999-08-30
ES2356595T3 (es) 2011-04-11
JP4372345B2 (ja) 2009-11-25

Similar Documents

Publication Publication Date Title
ATE354590T1 (de) Neue antidiabetische peptide
Urva et al. The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists
MY134820A (en) Glucagon-like insulinotropic complexes, compositions and methods
DE69943039D1 (de) Neue verbindungen mit gemischter amylin aktivität
IL144703A0 (en) Methods and reagents for treating glucose metabolic disorders
NO20010982L (no) Fremgangsmåte for å administrere insulinotropiske peptider
Wang et al. Efficacy and safety of once‐weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: a 52‐week open‐label, randomized phase III trial
ATE273996T1 (de) Zusammensetzung zur therapie von diabetes mellitus und fettsucht
MX9201110A (es) Composicion para el tratamiento de la diabetes mellitus, la hypoglicemia y de otros padecimientos relacionados.
BRPI0606727A (pt) terapia de combinação para o tratamento de diabetes e condições relacionadas com ele e para o tratamento de condições melhoradas através de aumento no nìvel de glp-1 no sangue
UA92451C2 (en) Polyethelene glycol link glp-1 compounds
CA2373266A1 (en) Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
EA201101191A1 (ru) Фармацевтическая композиция, включающая ингибитор sglt-2, ингибитор дпп-iv и необязательно другой антидиабетический агент, и ее применение
RU2008110504A (ru) Способы лечения диабета и снижения массы тела
EP1145717A3 (de) Synergistische Wirkung von einem Sulfonylharnstoff und/oder einem nicht Sulfonylharnstoff K-ATP Kanalblocker und einem cAMP-Phosphodiestrerase Typ 3 Inhibitor
WO2006096565A3 (en) Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
EA200900626A1 (ru) Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и содержащими их фармацевтическими композициями
NO20015932L (no) Fremgangsmåte til å behandle diabetes
BR9106225A (pt) Componente betume/polimero que permite obter composicoes de betume/polimero de suscetibilidade termica muito baixa utilizaveis para a realizacao de revestimentos
WO2005070444A8 (en) Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
WO2006136423A3 (en) Medicament for the treatment of impaired glucose metabolism
TR200000134T2 (tr) Tiazolidinedion, ensülin salgılatıcısı ve biguanid ile diabetin (şeker hastalığının) tedavisi.
BRPI0412182A (pt) composição para tratamento e/ou prevenção de disfunções associadas com diabetes melito do tipo 2 e resistência à insulina
Lv et al. Comparison of a multiple daily insulin injection regimen (glargine or detemir once daily plus prandial insulin aspart) and continuous subcutaneous insulin infusion (aspart) in short‐term intensive insulin therapy for poorly controlled type 2 diabetes patients
BRPI0506793A (pt) métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties